Company: PACB
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0001299130-25-000090
Chunk: 32

Company: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 32
---
, 2024. These amounts have been computed in accordance with FASB ASC 718. Pursuant to SEC rules, the amounts shown exclude the impact of estimated forfeitures related to service-based vesting conditions. For a discussion of valuation assumptions, see the notes to our financial statements included in our Annual Report.

(3) The aggregate number of shares subject to outstanding RSUs and stock options outstanding and exercisable as of December 31, 2024 for each non-employee director is as follows:

| Name(1)                   |     | Aggregate   
 Number of   
 RSUs        
 Outstanding |        |     | Aggregate     
 Number of     
 Stock Options 
 Outstanding   |         |     | Aggregate     
 Number of     
 Stock Options 
 Exercisable   |         |
| William Ericson           |     |             | 22,821 |     |               | 280,353 |     |               | 264,263 |
| Randy Livingston          |     |             | 22,821 |     |               | 280,353 |     |               | 264,263 |
| David Meline(4)           |     |             | 17,116 |     |               | 111,088 |     |               |  45,882 |
| John F. Milligan, Ph.D.   |     |             | 22,821 |     |               | 265,353 |     |               | 249,263 |
| Marshall Mohr             |     |             | 22,821 |     |               | 280,353 |     |               | 264,263 |
| Kathy Ordoñez(5)          |     |             | 22,821 |     |               | 180,353 |     |               | 164,263 |
| Lucy Shapiro, Ph.D.       |     |             | 22,821 |     |               | 263,687 |     |               | 247,597 |
| Hannah A. Valantine, M.D. |     |             | 22,821 |     |               | 149,961 |     |               | 133,871 |

(4) Mr. Meline resigned from our Board of Directors effective January 30, 2025.

(5) Ms. Ordoñez’s amounts include certain stock options granted to her during her tenure as our Chief Commercial Officer and Executive Vice President from October 2017 to October 2018.

| 2025 Proxy Statement |